{
    "root": "ab9c214d-f2e3-4043-b2da-b6a56a8b0432",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Heparin Sodium",
    "value": "20250122",
    "ingredients": [
        {
            "name": "heparin sodium",
            "code": "ZZ45AB24CA"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "benzyl alcohol",
            "code": "LKG8494WBH"
        },
        {
            "name": "hydrochloric acid",
            "code": "QTT17582CB"
        },
        {
            "name": "sodium hydroxide",
            "code": "55X04QC32I"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "heparin sodium injection indicated : prophylaxis treatment venous thrombosis pulmonary embolism ; prevention postoperative deep venous thrombosis pulmonary embolism patients undergoing major abdominothoracic surgery , reasons , risk developing thromboembolic disease ; atrial fibrillation embolization ; treatment acute chronic consumptive coagulopathies ( disseminated intravascular coagulation ) ; prevention clotting arterial cardiac surgery ; prophylaxis treatment peripheral arterial embolism . anticoagulant blood transfusions , extracorporeal circulation , dialysis procedures .",
    "contraindications": "recommended adult dosages : therapeutic anticoagulant effect full-dose heparin sodium † ( 2.4 ) † based 150 lb ( 68 kg ) patient . adjust dose based laboratory monitoring . deep subcutaneous ( intrafat ) injection different site injection initial dose 5,000 units intravenous injection , followed 10,000 20,000 units concentrated solution , subcutaneously every 8 hours every 12 hours 8,000 10,000 units concentrated solution 15,000 20,000 units concentrated solution intermittent intravenous injection initial dose 10,000 units , either undiluted 50 100 ml 0.9 % sodium chloride injection , usp every 4 6 hours 5,000 10,000 units , either undiluted 50 100 ml 0.9 % sodium chloride injection , usp intravenous infusion initial dose 5,000 units intravenous injection continuous 20,000 40,000 units/24 hours 1,000 ml 0.9 % sodium chloride injection , usp ( compatible solution ) infusion",
    "warningsAndPrecautions": "heparin sodium injection , usp preserved benzyl alcohol available following strength package size : ndc heparin sodium injection , usp ( 5,000 usp units per ml ) package factor 71288-406-82 5,000 usp units per 1 ml , prefilled single-dose syringe 24 syringes per carton",
    "adverseReactions": "heparin sodium contraindicated patients following conditions : history heparin-induced thrombocytopenia heparin-induced thrombocytopenia thrombosis [ ( 5.3 ) ] ; known hypersensitivity heparin sodium pork products ( e.g . , anaphylactoid ) [ ( 6.1 ) ] ; suitable blood coagulation tests , e.g . , whole blood clotting time , partial thromboplastin time , etc . , performed appropriate intervals ( contraindication refers full-dose heparin sodium ; usually need monitor coagulation parameters patients receiving low-dose heparin sodium ) ; uncontrolled active bleeding state [ ( 5.2 ) ] , except due disseminated intravascular coagulation .",
    "indications_original": "Heparin Sodium Injection is indicated for:\n\n                  \n                     Prophylaxis and treatment of venous thrombosis and pulmonary embolism;\n\n                     Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease;\n\n                     Atrial fibrillation with embolization;\n\n                     Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation);\n\n                     Prevention of clotting in arterial and cardiac surgery;\n\n                     Prophylaxis and treatment of peripheral arterial embolism.\n\n                     Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.",
    "contraindications_original": "Recommended Adult Dosages: Therapeutic Anticoagulant Effect with Full-Dose Heparin Sodium † ( 2.4 ) † Based on 150 lb (68 kg) patient. Adjust dose based on laboratory monitoring. Deep Subcutaneous (Intrafat) Injection Use a different site for each injection Initial Dose 5,000 units by intravenous injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously Every 8 hours or Every 12 hours 8,000 to 10,000 units of a concentrated solution 15,000 to 20,000 units of a concentrated solution Intermittent Intravenous Injection Initial dose 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Every 4 to 6 hours 5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Intravenous Infusion Initial dose 5,000 units by intravenous injection Continuous 20,000 to 40,000 units/24 hours in 1,000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion",
    "warningsAndPrecautions_original": "Heparin Sodium Injection, USP preserved with benzyl alcohol is available in the following strength and package size:\n\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              NDC\n                           \n                           \n                              Heparin Sodium Injection, USP (5,000 USP units per mL)\n                           \n                           \n                              Package Factor\n                           \n                        \n                        \n                           71288-406-82\n\n                           5,000 USP units per 1 mL, Prefilled Single-Dose Syringe\n\n                           24 syringes per carton",
    "adverseReactions_original": "The use of heparin sodium is contraindicated in patients with the following conditions:\n                  \n                     History of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see Warnings and Precautions (5.3)];\n                     Known hypersensitivity to heparin sodium or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions (6.1)];\n                     In whom suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin sodium; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin sodium);\n                     An uncontrolled active bleeding state [see Warnings and Precautions (5.2)], except when this is due to disseminated intravascular coagulation."
}